-
Mashup Score: 1
The phase 2b VIRAGE study will investigate the safety and efficacy of VCN-01 plus standard chemotherapy in patients with first-line pancreatic ductal adenocarcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Mitazalimab and Chemotherapy Induces Antitumor Activity in mPDAC - 11 month(s) ago
Durable responses in patients with metastatic pancreatic ductal adenocarcinoma treated with mitazalimab plus chemotherapy have led to discussions with regulatory authorities.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Mitazalimab + chemotherapy reached deep tumor responses in patients with metastatic pancreatic ductal adenocarcinoma, according to findings from the phase 2 OPTIMIZE-1 study. #PDAC #gicsm https://t.co/qKOK3FkHzK
-
-
Mashup Score: 0Source: link.springer.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Achieving measurable quality metric standards improves outcomes in #PDAC Grateful to @AnnSurgOncol for the opportunity to share our work. Access our recent 📰 from @HollySpitz13 and team 👇 https://t.co/moULyOrEEe @lexyadams16 @elizcarpenter16 @vreelant @CDTzeng @mkatzmd https://t.co/cUMsABnlGp
-
-
Mashup Score: 0FDA Accepts sNDA for First-Line NALIRIFOX in Metastatic PDAC - 11 month(s) ago
Data from the phase 3 NAPOLI 3 trial have led the FDA to accept a supplemental new drug application for NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The #FDA has accepted a sNDA for #NALIRIFOX as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma . #PDAC #gicsm https://t.co/yVfEhbEzW6
-
-
Mashup Score: 0Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance - 11 month(s) ago
Pancreatic cancer surveillance is critical to decreasing pancreatic cancer mortality; therefore, it is important that pancreatic cancer surveillance studies enroll diverse patients. We demonstrate that substantial racial/ethnic- and sex-based disparities exist amongst enrollment in the international PRECEDE consortium, highlighting the dire need for future efforts to reduce these disparities.
Categories: Hem/Oncs, Latest HeadlinesTweet-
A call to action - Racial, Ethnic and Sex-based Disparities Among HRIs Undergoing #PDAC Surveillance. #pancsm #earlydetection @PrecedeStudy https://t.co/hY8S5NaOVi
-
-
Mashup Score: 0Wolters Kluwer Health - 11 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Oncs, Latest HeadlinesTweet-
While I was sorry to miss @SyedAAhmad5 talk @ASCO #ASCO23, grateful for his amplification of our commentary in @AnnalsofSurgery 👉🏽https://t.co/sTkaC8nR3m re exercising caution in overinterpreting exceptional outcomes following arterial resection in #PDAC👇🏽 @NbmerchantMD @mkatzmd https://t.co/MyUBMv7WnQ
-
-
Mashup Score: 3NALIRIFOX Delivers Substantial Survival Advantage to Patients With mPDAC - 11 month(s) ago
An update from the phase 3 NAPOLI 3 trial supports the use of NALIRIFOX for the first-line treatment of metastatic pancreatic ductal adenocarcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to the phase 3 NAPOLI 3 study presented at #ASCO2023, statistically significant and clinically meaningful improvements in OS & PFS were achieved with #NALIRIFOX in patients with treatment-naïve metastatic #PDAC. #pancsm | @MSKCancerCenter https://t.co/lbAELacpe4
-
-
Mashup Score: 0Brg1 controls stemness and metastasis of pancreatic cancer through regulating hypoxia pathway - Oncogene - 12 month(s) ago
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. We previously reported that chromatin remodeler Brg1 is essential for acinar cell-derived PDAC formation in mice. However, the functional role of Brg1 in established PDAC and its metastasis remains unknown. Here, we investigated the importance of Brg1 for established PDAC by using a mouse model with a dual recombinase system. We…
Source: NatureCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#New study shows that Brg1 plays a crucial role for cell survival and growth of spontaneously developed #PDAC by regulating HIF-1α #binding to the hypoxia responsive elements to directly regulate target gene expression. Read more 👉 https://t.co/NW08sw5CK3
-
-
Mashup Score: 0
In an interview with Targeted Oncology, Zev A. Wainberg, MD, discussed the rationale behind NAPOLI 3 and how findings from the study will influence the metastatic pancreatic ductal adenocarcinoma space moving forward.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Here, Zev A. Wainberg, MD, discussed the rationale and findings from the NAPOLI 3 study for patients with metastatic pancreatic ductal adenocarcinoma. #PDAC #pancsm | @UCLAHealth https://t.co/VSVgtOiJq0
-
-
Mashup Score: 1Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer - Nature - 1 year(s) ago
A phase I clinical trial of an adjuvant personalized mRNA neoantigen vaccine, autogene cevumeran, in patients with pancreatic ductal carcinoma demonstrates that the vaccine can induce T cell activity that may correlate with delayed recurrence of disease.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
27. Can #mRNAvaccine expanded T cells detect micrometastases? Interesting clinical vignette in Figure 4 👉🏽 here https://t.co/d1SgGgdVHq.
-
9. So, in 2017, we partnered with Ira Mellman @Genentech + Ugur Sahin @BioNTech_Group, to answer: Are #mRNAvaccinesagainst NAs in #PDAC 1) Feasible (despite #PDACs have few NAs)? 2) Safe? 3) Able to activate T cells? Now answers in @nature https://t.co/d1SgGgdVHq.
-
The #FDA has granted an ODD to VCN-01 + standard chemotherapy doublet of gemcitabine and nab-paclitaxel for the frontline treatment of patients with pancreatic ductal adenocarcinoma. #PDAC #gicsm https://t.co/vDamq4P6Zf